Furthermore, we observed an increased nuclear S100A15 expression in lung cancer tissues not only in stage IV NSCLC compared to stage IIIB NSCLC, but also in the patients with stable or progressive disease in comparison to those with a partial response after first line combination chemotherapy with CDDP and GEM. The gene discussed is S100A7A; the disease is lung cancer.